$165MSeries A, 9 October 2025
Funds a global Phase 2 COPD trial of EXPD-101.
- Amount
- $165M
- Stage
- Series A
- Announced
- 9 October 2025
- Lead
- Sofinnova Investments
- Other investors
- Novo Holdings, Forbion, Dawn Biopharma, Adage, Balyasny, Logos Capital, Sanofi Ventures
- Use of funds
- Funds a global Phase 2 COPD trial of EXPD-101.
- Checked
- Announced by the company
- Sources
- Expedition Therapeutics Raises $165 Million in Oversubscribed Series A Financing to Advance Next-Generation DP businesswire.com
Expedition Therapeutics Raises $165 Million in Oversubscribed Series A Financing to Advance Next-Generation DP news.google.com
Expedition Therapeutics Raises $165 Million in Oversubscribed Series A Financing to Advance Next-Generation DP news.crunchbase.com